Scientists have found that the immune regulation of mesenchymal stem cells has such a plasticity, that is, it is like a moderator of the inflammatory environment: when the inflammatory response increases, mesenchymal stem cells inhibit the immune response; when the inflammatory response weakens, mesenchymal stem cells may promote the immune response  This characteristic needs to be paid great attention in the process of treating diseases  For example, scientists have found that mesenchymal stem cells entering the human body can significantly alleviate the condition of patients with liver cirrhosis, reduce the inflammatory reaction in the liver, and improve liver function indexes such as bilirubin and albumin  However, dexamethasone can counteract the therapeutic effect of mesenchymal stem cells on liver cirrhosis to a considerable extent  The reason is that when patients receive the combined treatment of dexamethasone and mesenchymal stem cells, the inflammation in the focus of patients with liver cirrhosis will be reduced, resulting in the weakening of the immunosuppressive effect of mesenchymal stem cells and the complete disappearance of the therapeutic effect of mesenchymal stem cells
it may even aggravate the disease
The combined use of mesenchymal stem cells and some drugs may undermine their therapeutic effect on inflammatory diseases.